Adagio Medical Holdings (ADGM) Q3 2024 earnings summary

Executive summary

• Completed a business combination with ARYA Sciences Acquisition Corp IV on July 31, 2024, resulting in a new public entity listed on Nasdaq as ADGM and recapitalization.

• Revenue for Q3 2024 reached $185,000, a 351% increase year-over-year, driven by vCLAS adoption and commercial launch in the EU; U.S. launch pending regulatory approval.

• Focused on expanding clinical studies and commercial adoption of ablation technologies for cardiac arrhythmias in the US and Europe.

• Net income of $3.6 million for the Successor period (July 31–Sept 30, 2024) following a $21.3 million loss in the Predecessor period (Jan 1–July 30, 2024); net loss narrowed to $4.6 million from $10.8 million year-over-year.

• Accumulated deficit reduced to $13.2 million as of September 30, 2024, from $133.6 million at December 31, 2023.

Financial highlights

• Revenue for Q3 2024 was $185,000, up 351% year-over-year, driven by increased consumable sales in Europe and vCLAS adoption.

• Gross margin improved to negative 209% in Q3 2024 from negative 517% in Q3 2023, but remained negative due to high cost of revenue relative to sales.

• Operating expenses rose to $10.2 million from $8.9 million year-over-year, mainly due to transaction and public company costs; R&D expenses decreased 44% to $1.2 million for the Successor period.

• Net cash used in operating activities was $6.4 million for the Successor period, with $28.3 million in cash, cash equivalents, and short-term investments at September 30, 2024.

• Basic EPS for the Successor period was $0.18; diluted EPS was $0.02, reflecting adjustments for convertible securities.

Outlook and guidance

• Management expects continued operating losses and negative cash flows for several years as commercialization and development continue.

• Current cash is not sufficient to fund operations for the next 12 months; additional financing will be required.

• Plans include seeking new equity or debt financing, pursuing U.S. regulatory approvals, and implementing cost-cutting measures.

• Anticipates rapid increase in FULCRUM-VT IDE study enrollment and active centers following CMS coverage.

• Expects continued growth in vCLAS procedures and commercial adoption in targeted European centers.